~50%

of recurrent CV events in the first year occur in the first 90 days following an AMI1,2

~50% of recurrent CV events in the first year occur in the first 90 days following an AMI1,2

Continue

down
warning

Could excess cholesterol in atherosclerotic plaque be part of the problem?

As cholesterol cannot be broken down by the body, a two-way process of influx and efflux moves cholesterol into and out of arterial plaques.3

Any imbalance between influx and efflux causes plaques to gradually become engorged with excess cholesterol.4–7

As plaque burden increases, plaques may become vulnerable to rupture, which could lead to a fatal CV event, non-fatal AMI or stroke.1,4,5,7

In the high-risk 90-day period after an AMI, already compromised cholesterol efflux continues to diminish further, increasing the risk of a recurrent CV event.1, 7-11

Learn more about how cholesterol efflux can reduce the risk of recurrent CV events7,12

Read on

More on cholesterol efflux

The cholesterol story

Learn about the role of cholesterol efflux in removing excess cholesterol from lipid-laden macrophages in arterial plaque7,12

Learn more

Impact of low cholesterol efflux

Understand why a continued reduction in already impaired cholesterol efflux directly after an AMI increases the risk of a recurrent CV event8–10,13–15

Find out more

What happens to cholesterol efflux after an AMI?

Learn about why patients are at a disproportionately high risk in the 90-day period post AMI1,15–18

Get more info

Burden of recurrent CV events

Find out about the significant healthcare costs associated with recurrent CV events post AMI19–22

See more

Current standard of care post AMI

Current standard of care and newer therapies have lowered the  long-term risk of recurrent CV events; however, data show that  patients are still at risk during the 90-day high-risk period after  an AMI23-30

Discover more

Expert views

These resources are for global healthcare professionals to learn more about the role of cholesterol efflux and educate their patients after an AMI

Access more here right

Contact us

You can contact us by phone, fax or email

Get to know us right

Get the latest news

Sign up to receive news alerts and information about educational resources to help your patients through the 90-day high-risk period post AMI

By submitting this form, you are consenting to disclose any information provided, including your name, email address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may be contacted by mail, email, telephone, and/or SMS/text message in relation to our business, products, services, and educational programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt-out from receiving communications from CSL Behring Entities at any time. CSL Behring and CSL Behring Entities will not sell your personal information. CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Abbreviations

AMI, acute myocardial infarction; CV, cardiovascular

References

1. Chi G et al. Clin Cardiol 2022; 45:299–307.

2. Jernberg T et al. Eur Heart J 2015; 36:1163–1170.

3. Angelin B et al. Atheroscler Suppl 2002; 3:23–30.

4. Pepine CJ. Am J Cardiol 1998; 82:23S–27S.

5. Wentzel JJ et al. Cardiovasc Res 2012; 96:234–243.

6. Kingwell BA, Chapman MJ. Circulation 2013; 128:1112–1121.

7. Estrada-Luna D et al. Molecules 2018; 23:2730.

8. Soares AAS et al. Clin Chim Acta 2018; 478:51–56.

9. Ross R. N Engl J Med 1999; 340:115–126.

10. Rader DJ et al. J Lipid Res 2009; 50 Suppl:S189–S194.

11. Rached F et al. Biochim Biophys Acta 2015; 1851:1254–1261.

12. Silvain J et al. Curr Opin Cardiol 2019; 34:714–720.

13. Ray KK et al. Eur Heart J 2014; 35:1792–1800.

14. Saleheen D et al. Lancet Diabetes Endocrinol 2015; 3:507–513.

15. Rohatgi A et al. N Engl J Med 2014; 371:2383–2393.

16. Piepoli MF et al. Eur J Prev Cardiol 2016; 23:1994–2006.

17. Guerin M et al. J Am Coll Cardiol 2018; 72:3259–3269.

18. Zhang J et al. Am J Cardiol 2016; 117:508–514.

19. Bakhai A et al. J Interv Cardiol 2012; 25:19–27.

20. Punekar RS et al. Clin Cardiol 2015; 38:483–491.

21. Zhao Z, Winget M. BMC Health Serv Res 2011; 11:35.

22. Chapman RH et al. BMC Cardiovasc Disord 2011; 11:11.

23. Schwartz GG et al. N Engl J Med 2018; 379:2097–2107.

24. Cannon CP et al. N Engl J Med 2015; 372:2387–2397.

25. Schwartz GG et al. JAMA 2001; 285:1711–1718.

26. Bhatt DL et al. N Engl J Med 2019; 380:11–22.

27. Bhatt DL et al. J Am Coll Cardiol 2019; 73:2791–2802.

28. Mehta SR et al. N Engl J Med 2019; 381:1411–1421.

29. Wallentin L et al. N Engl J Med 2009; 361:1045–1057.

30. Nair R et al. J Am Heart Assoc 2021; 10:e019270.

USA-GEN-0051 | August 2023